The aim of this phase II randomised trial ( GFPC0501 ) is to compare , in patients with progressive SCLC after first-line platinum based chemotherapy , oral multi drug chemotherapy ( CCNU , cyclophosphamide , etoposide ) and classical intravenous chemotherapy with cyclophosphamide , doxorubicin and vincristine ( CAV ) in terms of tolerability , efficacy ( response rate , median one year survival and overall survival ) , quality of life and consumption of health care resources .
